153 Results for "

recombinant antibody

" in MedChemExpress (MCE) Product Catalog:
Products (153)

153 Results for "recombinant antibody" in MCE Product Catalog:

13
13 Publications Verification
Cat. No.: HY-K0218A

MCE Streptavidin Agarose 6FF, a 6% highly cross-linked agarose reagent coupled with recombinant streptavidin, is an affinity chromatography medium for separation and purification of biotinylated peptides, antibodies, lectins, etc. The total binding capacity of Streptavidin Agarose 6FF is more than 200 nmol of D-Biotin/mL settled resin.

loading...
    loading...
11
11 Cited Publications
Cat. No.: HY-K0214

MCE Protein G Agarose, a 4% highly cross-linked agarose reagent coupled with recombinant Protein G, effectively purifies mammalian monoclonal and polyclonal antibodies, such as human IgG3 and rat IgG2a.

loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-K0213

MCE Protein A Agarose, a 4% highly cross-linked agarose reagent coupled with recombinant Protein A, effectively purifies mammalian monoclonal and polyclonal antibodies, such as human IgG, IgE, IgM.

loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-P99156
CAS No.: 1673516-98-7
Synonyms: BMS-986016

Target:  

LAG-3

Research Areas:  

Cancer

Relatlimab (BMS-986016) is a human monoclonal antibody anti-LAG-3 antibody generated by immunization of transgenic mice bearing human immunoglobulin miniloci with recombinant LAG-3 protein. Relatlimab blocks LAG-3/MHC II interaction with an IC50 value of 0.67 nM and LAG-3/FGL1 interaction with an IC50 value of 0.019 nM. Relatlimab can be used in research of cancer .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-108831A
CAS No.: 189261-10-7
Purity:  98.72%
Synonyms: AN100226; BG00002
Natalizumab (Anti-CD49d) (AN100226; BG00002) Solution is a humanized monoclonal IgG4 antibody inhibitor that selectively targets α4 integrin (CD49d), blocking the interaction of integrins such as α4β1 (VLA-4) with vascular cell adhesion molecule VCAM-1, intercellular adhesion molecule ICAM-1, and fibronectin by competitively binding to the α4 subunit. Natalizumab solution inhibits the adhesion, retention, and transendothelial migration of immune cells (such as CD4 + T cells), reducing the infiltration of inflammatory cells into the central nervous system or lesion sites, thereby exerting anti-inflammatory and immunomodulatory activity. Natalizumab (Anti-CD49d) solution is used in the study of relapsing-remitting multiple sclerosis (RRMS) and is also applied in the research of autoimmune or inflammation-related diseases such as Crohn's disease, B-cell lymphoma, and non-infectious uveitis. Natalizumab (Anti-CD49d) can also prevent lymphocytes from entering the central nervous system, thus preventing acute demyelinating relapses .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P99305
CAS No.: 272780-74-2
Synonyms: CAT-192; Anti-TGFB1 recombinant antibody

Target:  

TGF-β Receptor

Research Areas:  

Inflammation/Immunology

Metelimumab (CAT-192) is a human IgG4 monoclonal antibody that can selectively neutralize TGFβ1 .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P99037
CAS No.: 2211985-36-1
Synonyms: M281

Target:  

Fc Receptor (FcR)

Research Areas:  

Inflammation/Immunology

Nipocalimab (M281) is a fully humanized, recombinant, and non-glycosylated IgG1 monoclonal antibody. Nipocalimab can bind to the IgG-binding site of FcRn with high affinity and inhibit the transplacental transfer of IgG. Nipocalimab can be used in the research of fetal and neonatal hemolytic disease, myasthenia gravis, and various IgG-mediated autoimmune diseases .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P99275
CAS No.: 1262787-83-6
Synonyms: AMG-888; U3-1287

Target:  

EGFR Akt ERK PARP Survivin

Research Areas:  

Cancer

Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P99288
CAS No.: 946415-13-0
Synonyms: Pamrevlumab; Anti-Human CTGF recombinant antibody

Target:  

Apoptosis

Research Areas:  

Inflammation/Immunology

FG-3019 (Pamrevlumab) is a recombinant human antibody that binds to connective tissue growth factor (CTGF). FG-3019 can be used for the research of idiopathic pulmonary fibrosis (IPF) .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P99279
CAS No.: 648904-28-3
Synonyms: Anti-Human Phosphatidylserine recombinant antibody; PGN-401; CH3G4

Target:  

Inhibitory Antibodies

Research Areas:  

Cancer

Bavituximab (Anti-Human Phosphatidylserine Recombinant Antibody) is a phosphatidylserine (PS)-targeting monoclonal antibody, suppresses tumor growth by targeting tumor vasculature and reactivating antitumor immunity. Bavituximab plus Paclitaxel (HY-B0015) and Carboplatin (HY-17393), have enhanced inhibition on non-small-cell lung cancer .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P9953
CAS No.: 428863-50-7
Synonyms: Certolizumab; CDP870

Target:  

TNF Receptor

Research Areas:  

Inflammation/Immunology Cancer

Certolizumab pegol (Certolizumab) is a recombinant, polyethylene glycosylated, antigen-binding fragment of a humanized monoclonal antibody that selectively targets and neutralizes tumour necrosis factor-α (TNF-α). Certolizumab pegol can be used for rheumatoid arthritis and Crohn disease research .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P99756
CAS No.: 1989556-22-0
Synonyms: MEDI8897

Target:  

RSV

Research Areas:  

Infection

Nirsevimab (MEDI8897) is a recombinant monoclonal antibody against human respiratory syncytial virus (RSV). Nirsevimab has neutralizing activity against RSV A and RSV B viruses, with IC50 values of 5.42 ng/mL and 9.71 ng/mL, respectively. Nirsevimab can be used for research on respiratory infections .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-108810
CAS No.: 914613-48-2
Purity:  99.64%
Synonyms: Ilaris; ACZ 885
Canakinumab (ACZ885) is a recombinant human anti-IL-1β monoclonal antibody. Canakinumab shows IC50 values of 43.6 and 40.8 pM for human and marmoset IL-1β, respectively. The mode of action of canakinumab is based on the neutralization of IL-1β signaling, resulting in suppression of inflammation related to disorders of autoimmune origin .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99280
CAS No.: 1418205-77-2
Synonyms: CDP4940; UCB-4940

Target:  

Interleukin Related

Research Areas:  

Inflammation/Immunology

Bimekizumab (Anti-Human IL17A/IL-17F Recombinant Antibody) is a humanised monoclonal antibody, can selectively neutralises IL-17A and IL-17F. Both of them are pro-osteogenic with respect to human periosteum-derived cell (hPDC) differentiation. Thus Bimekizumab blocks the inflammation-driven osteogenic differentiation .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99264
CAS No.: 1660159-36-3
Synonyms: Humanized Anti-CD22 recombinant antibody
Research Areas:  

Cancer

Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) is a humanized IgG4κ antibody that targets human CD22. Inotuzumab can be linked to a toxic agent Ozogamicin as an antibody-drug conjugate (ADC), Inotuzumab ozogamicin (HY-P9959). Inotuzumab can be used for the research of acute lymphoblastic leukemia and non-Hodgkin lymphoma .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99269
CAS No.: 216669-97-5
Synonyms: BIBH 1; Anti-Human FAP recombinant antibody

Target:  

FAP

Research Areas:  

Cancer

Sibrotuzumab (BIBH 1) is a humanized IgG1 monoclonal antibody targets fibroblast activation protein (FAP). Sibrotuzumab can be used for the research of colorectal cancer and non-small cell lung cancer (NSCLC) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99294
CAS No.: 905703-97-1
Synonyms: AMG 479; Human Anti-IGF1R recombinant antibody

Target:  

IGF-1R

Research Areas:  

Cancer

Ganitumab (AMG 479) is a recombinant human monoclonal antibody to the human type 1 insulin-like growth factor receptor (IGF1R). Ganitumab recognizes murine IGF1R with sub-nanomolar affinity (KD=0.22 nM) and inhibits the interaction of murine IGF1R with IGF1 and IGF2. Ganitumab can be used in research of cancer .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99300
CAS No.: 1322627-61-1
Synonyms: QGE 031; Anti-IGHE recombinant antibody

Target:  

Fc Receptor (FcR)

Research Areas:  

Inflammation/Immunology

Ligelizumab (QGE 031) is a humanized high-affinity anti-immunoglobulin IgE monoclonal antibody. Ligelizumab selectively inhibits the binding of IgE to the high-affinity receptor FcεRI, while the inhibitory effect on the low-affinity receptor CD23 is weak. Ligelizumab can inhibit the activation of effector cells such as mast cells and Basophil, while reducing the production of IgE by B cells, and restoring the IFN-α production and regulatory T cell (Treg) induction function of plasmacytoid dendritic cells (pDC). Ligelizumab can be used in the study of allergic diseases (such as chronic spontaneous urticaria, allergic asthma) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99271
CAS No.: 1418628-81-5
Synonyms: Anti-Human F3 recombinant antibody

Target:  

ADC Antibodies

Research Areas:  

Cancer

Tisotumab (Anti-Human F3 Recombinant Antibody) is a human IgG1 monoclonal antibody and ADC antibody. Tisotumab targets tissue factor (TF). Tisotumab can be used to synthesize antibody-drug conjugates (ADCs) targeting tissue factor (TF), Tisotumab vedotin (HY-152963). Tisotumab can be used for the research of solid tumors .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99274
CAS No.: 1417158-65-6
Synonyms: BI 836845; Anti-Human IGF1 and IGF2 recombinant antibody

Target:  

IGF-1R

Research Areas:  

Cancer

Xentuzumab (Anti-Human IGF1 and IGF2 Recombinant Antibody; BI836845) is a recombinant a human monoclonal antibody that targets IGF ligands IGF1 and IGF2. Xentuzumab inhibits both of IGF1 and IGF2 growth-promoting signalling and suppresses AKT activation .
loading...
    loading...